Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) and Cellectar Biosciences (NASDAQ:CLRB) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, profitability, earnings, analyst recommendations, institutional ownership, risk and valuation.
Insider and Institutional Ownership
10.1% of Adamis Pharmaceuticals Corporation shares are held by institutional investors. Comparatively, 2.6% of Cellectar Biosciences shares are held by institutional investors. 12.2% of Adamis Pharmaceuticals Corporation shares are held by insiders. Comparatively, 10.2% of Cellectar Biosciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Valuation and Earnings
This table compares Adamis Pharmaceuticals Corporation and Cellectar Biosciences’ gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||EBITDA||Earnings Per Share||Price/Earnings Ratio|
|Adamis Pharmaceuticals Corporation||$11.39 million||14.52||-$18.97 million||N/A||N/A|
|Cellectar Biosciences||N/A||N/A||-$10.78 million||($1.24)||-1.38|
Cellectar Biosciences has higher revenue, but lower earnings than Adamis Pharmaceuticals Corporation.
This table compares Adamis Pharmaceuticals Corporation and Cellectar Biosciences’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Adamis Pharmaceuticals Corporation||-158.51%||-69.03%||-47.51%|
Risk and Volatility
Adamis Pharmaceuticals Corporation has a beta of 0.02, indicating that its share price is 98% less volatile than the S&P 500. Comparatively, Cellectar Biosciences has a beta of 1.03, indicating that its share price is 3% more volatile than the S&P 500.
This is a summary of recent recommendations for Adamis Pharmaceuticals Corporation and Cellectar Biosciences, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Adamis Pharmaceuticals Corporation||0||0||3||0||3.00|
Adamis Pharmaceuticals Corporation currently has a consensus target price of $9.83, suggesting a potential upside of 86.41%. Cellectar Biosciences has a consensus target price of $2.70, suggesting a potential upside of 57.43%. Given Adamis Pharmaceuticals Corporation’s higher possible upside, research analysts plainly believe Adamis Pharmaceuticals Corporation is more favorable than Cellectar Biosciences.
Adamis Pharmaceuticals Corporation beats Cellectar Biosciences on 7 of the 10 factors compared between the two stocks.
Adamis Pharmaceuticals Corporation Company Profile
Adamis Pharmaceuticals Corporation is a pharmaceutical company. The Company is engaged in the development of its specialty pharmaceutical products. The Company is developing various products in the allergy and respiratory markets, including a dry powder inhaler technology that it acquired from 3M Company (3M). The Company’s product portfolio includes specialty pharmaceutical products, such as Epinephrine pre-filled syringe (PFS), APC-5000 dry powder inhaler (DPI), APC-1000 and APC-2000, and biotechnology products, such as TeloB-VAX (vaccine), APC-100, APC-200 and APC-300. The Company’s lead product candidate, the Epinephrine Injection USP 1:1000 0.3 milligram Pre-filled Single Dose Syringe, or the Epinephrine PFS, is a pre-filled syringe designed to deliver a premeasured 0.3 milligrams dose of epinephrine for the treatment of anaphylaxis. The Company also has licensed vaccine technology called somatic transgene immunization (STI) technology.
Cellectar Biosciences Company Profile
Cellectar Biosciences, Inc., formerly Novelos Therapeutics, Inc., is a clinical stage biopharmaceutical company. The Company is engaged in developing phospholipid ether-drug conjugates (PDCs) for the treatment and diagnostic imaging of cancer. Its research and development program is based on its PDC cancer targeting delivery platform. Its pipeline consists of pre-clinical and clinical product candidates, including radiotherapeutic and chemotherapeutic PDC’s. The Company’s PDC product portfolio includes CLR 131, which is designed to deliver cytotoxic (cell-killing) radiation directly and selectively to cancer cells and cancer stem cells; CLR 125, which is for the treatment of micro metastatic disease; CLR 124, which is a cancer-targeting positron emission tomography (PET) imaging PDC; CLR 1502, which is for intraoperative tumor margin illumination and non-invasive tumor imaging, and CTX Product Portfolio, including CLR 1601-PTX, CLR 1602-PTX and CLR 1603-PTX product candidates.
Receive News & Ratings for Adamis Pharmaceuticals Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adamis Pharmaceuticals Corporation and related companies with MarketBeat.com's FREE daily email newsletter.